BioXcel Therapeutics (BTAI) Profit After Tax (2017 - 2026)

BioXcel Therapeutics' Profit After Tax history runs 10 years deep, the most recent figure standing at -$12.7 million for Q1 2026.

• In Q1 2026, Profit After Tax fell 74.95% year-over-year to -$12.7 million; the TTM figure through Mar 2026 stood at -$75.3 million (down 88.04% YoY), while the FY2025 annual figure was -$69.9 million, down 17.28% from the prior year.
• Profit After Tax was -$12.7 million for Q1 2026 at BioXcel Therapeutics, down from -$12.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$7.3 million in Q1 2025 to a low of -$54.8 million in Q4 2022.
• Historically, Profit After Tax has averaged -$28.6 million across 5 years, with a median of -$26.8 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax jumped 84.49% in 2024, then tumbled 131.2% in 2025.
• A 5-year view of Profit After Tax shows it stood at -$54.8 million in 2022, then soared by 59.39% to -$22.3 million in 2023, then surged by 51.21% to -$10.9 million in 2024, then dropped by 15.53% to -$12.5 million in 2025, then retreated by 1.16% to -$12.7 million in 2026.
• The last three Profit After Tax figures came in at -$12.7 million (Q1 2026), -$12.5 million (Q4 2025), and -$30.9 million (Q3 2025), per Business Quant data.